Monthly Update: Central & Peripheral Nervous Systems: Pharmacology of antimigraine 5-HT_1D receptor agonists

References to Primarv Literature

• HUMPHREY PPA, FENIUK W, PERREN MJ, CONNOR HE, OXFORD AW, COATES IH, BUTINA D: GB 43175 a selective agonist for the 5-HTi-like receptor in dog isolated saphenous vein. Br. J. Pharmacol. (1988) 94:1123–1132.
   PubMed Web of Science ®Google Scholar
• FERRARI MD, SAXENA PR: Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. (1993) 14:129–133.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, MCTAVISH D: Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and duster headache. Drugs (1994) 47:622–651.
   Google Scholar
• SAXENA PR, TFELT-HANSEN P: Sumatriptan. In: The Head-ache. Olesen J, Tfeh-Hansen P, Welch KMA (Eds.), Raven Press, New York (1993):329–341.
   Google Scholar
• HUMPHREY PPA, APPERLEY E, FENIUK W, PERREN MJ: Arational approach to identifying a fundamentally new drug for the treatment of migraine. In: Cardiovascular Pharmacology of 5-Hydrarytryptamine, Prospective Thera-peutic Applications. Saxena PR, Wallis DI, Wouters W, Bevan P (Eds.), Kluwer Academic Publishers, Dordrecht (1990):417–428.
   Google Scholar
• SAXENA PR, FERRARI MD: From serotonin receptor clas-sification to the antimigraine drug sumatriptan. Cepha-lalgia (1992) 12:187–196.
   PubMed Web of Science ®Google Scholar
• SICUTERI F, TESTI A, ANSELMI B: Biochemical investiga-tions in headache: increase in the hydroxyindoleacetic add excretion during migraine attacks. Mt. Arch. Allergy (1961) 19:55–58.
   Web of Science ®Google Scholar
• ANTHONY M, HINTERBERGER H, LANCE JW: The possiblerelationship of serotonin to the migraine syndrome. Res. Clin. Stud. Headache (1969) 2:29–59.
   Google Scholar
• KIMBALL RW, FRIEDMAN AP, VALLEJO E: Effect of sero-tonin in migraine patients. Neurology (1960) 10:107–111.
   PubMed Web of Science ®Google Scholar
• SAXENA PR: The effects of antimigraine drugs on the vascular responses evoked by 5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: possible pharmacological implications to their antimigraine action. Headache (1972) 12:44–54.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, VAN HOUWELINGEN P, BONTA IL: The effectof mianserin hydrochloride on the vascular responses to 5-hydroxytryptamine and related substances. Eur. J. Pharmacol. (1971) 13:295–305.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, DUNCKER DJ, BOM AH, HEILIGERS J, VER-DOUW PD: Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: Evidence for the presence of vascular 5-hy-droxytryptaminel-like receptors. Naunyn-Schmiede-berg's Arch. Pharmacol. (1986) 333:198–204.
   Google Scholar
• SAXENA PR: Selective vasoconstriction in carotid vascu-lar bed by methysergide: Possible relevance to its an-timigraine action. Eur.J. Pharmacol. (1974) 27:99–105.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, DE VLAAM-SCHLUTER GM: Role of somebiogenic substances in migraine and relevant mecha-nism in antimigraine action of ergotAmine. Studies in an animal experimental model for migraine. Headache (1974) 13:142–163.
   Google Scholar
• JOHNSTON BM, SAXENA PR: The effect of ergotamine ontissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br. J. Pharmacol. (1978) 63:541–549.
   PubMed Web of Science ®Google Scholar
• SPIERINGS ELH, SAXENA PR: Antinulgraine drugs and cranial arteriovenous shunting in the cat. Neurology (1980) 30:696–701.
   PubMed Web of Science ®Google Scholar
• SPIERINGS ELH, SAXENA PR: Effect of isometheptene onthe distribution and shunting of 15 p.m microspheres throughout the cephalic circulation of the cat. Headache (1980) 20:103–106.
   Google Scholar
• HEYCK H: Pathogenesis of migraine. Res. din. Stud. Headache (1969) 2:1–28.
   Google Scholar
• SAXENA PR: Arteriovenous shunting and migraine. Re Clin. Stud. Headache (1978) 6:89–102.
   PubMedGoogle Scholar
• HUMPHREY PPA, FENIUK W, MARRIOTT AS, TANNER RJN, JACKSON MR, TUCKER ML: Preclinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. (1991) 31:282–290.
   PubMed Web of Science ®Google Scholar
• BRAND J, HADOKE M, PERRIN VL: Placebo controlled study of a selective 5-HTi-like agonist, A1125086B, in relief of acute migraine. Cephalalgia (1987) 7:402–403.
   Google Scholar
• DOENICKE A, SIEGEL E, FIADOICE M, PERRIN VL: Initialclinical study of AH25086B (5-M*1-like agonist) in the acute treatment of migraine. Cephalalgia (1987) 7:438–439.
   Google Scholar
• ADHAM N, KAO H-T, SCHECHTER LE, BARD J, OLSEN M,URQUHART D, DURKIN M, HARTIG PR, WEINSHANK RI, BRANCHEK TA: Cloning of another human serotonin receptor (5-HT2t): a fifth 5-HT1 receptor subtype cou-pled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Scl. USA (1993) 90:408–412.
   PubMed Web of Science ®Google Scholar
• BEATTIE DT, CONNOR HE, FENIUK W, HUMPHREY PPA:The pharmacology of sumatriptan. Rev. Contemp. Phar-macotber. (1994) 5:285–294.
   Google Scholar
• HOYER D: Functional correlates of serotonin 5-11T1 receptor site. J. Rec. Res. (1988) 8:59–81.
   PubMed Web of Science ®Google Scholar
• HOYER D, CLARICE DE, FOZARD JR, HARTIG PR, MARTIN GR, MYLECHARANE EJ, SAXENA PR, HUMPHREY PPA: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Phar-macol. Rev. (1994) 46:157–203.
   PubMed Web of Science ®Google Scholar
• PEROUTICA SJ, MCCARTHY BG: Sumatriptan (GR 43175) interacts selectively with 5-HTta and 5-HT1D binding sites. Eur. J. Pharmacol. (1989) 163:133–136.
   PubMed Web of Science ®Google Scholar
• SCHOEI.E-1ER P, HOYER D: How selective is GR 43175? Interactions with functional 5-HTIA, 5-HT1s, 5-HTit and 5-HTin receptors. Naunyn-Schmiedeberg's Arch. Pharma-col. (1989) 340:135–138,
   PubMed Web of Science ®Google Scholar
• SKINGLE M, SCOPES DIC, FENIUK W, CONNOR HE, CAR-TER MC, CLITHEROW JW, TYERS MB: GR127935: a potent orally active 5-HT1n receptor antagonist. Br. J. Pharma-col. (1993) 110:9P.
   Web of Science ®Google Scholar
• STARKEY SJ, SKINGLE M: 5-HT1D as well as 5-HT1A autore-ceptors modulate 5-HT release in the guinea-pig dorsal raphé nucleus. Neuropharmacology (1994) 33:393–402.
   PubMed Web of Science ®Google Scholar
• HAMEL E, BOUCHARD D: Contractile 5-HT1 receptors in human isolated pial arterioles: correlation with 5-HT2D binding sites. Br. J. Pharmacol. (1991) 102:227–233.
   PubMed Web of Science ®Google Scholar
• SCHOEFF1ER P, WAEBER C, PALACIOS JM, HOYER D: The 5-hydroxytryptamine 5-HT1D receptor subtype is nega-tively coupled to aclenylate cyclase in calf substantia nigra. Naunyn-Schmiedeberg's Arch. Pharmacol (1988) 337:602–608.
   Google Scholar
• WAEBER C, SCHOEFFTER P, PALACIOS JM, HOYER D: Molecular pharmacology of 5-HT10 recognition sites: radioligand binding studies in human, pig and calf brain membranes. Naunyn-Schmiedeberg'sArch. Pharma-col. (1988) 337:595–601.
   Google Scholar
• BAR WA, VAN HEUVEN-NOLSEN D, BOS E, SIMOONS ML, SAXENA PR: 5-Hydroxytryptamine-induced contrac-tions of the human isolated saphenous vein: involve-ment of 5-HT2 and 5-HTin-like receptors, and a comparison with 'grafted' veins. Naunyn-Schmiedeberg's Arch. Pharmacol. (1992) 345:500–508.
   Google Scholar
• DECKERT V, PRUNEAU D, ELGHOZI J-L: Mediation by 5-11Tin receptors of 5-hydroxytryptamine-induced con-tractions of rabbit middle and posterior cerebral arter-ies. Br. J. Pharmacol. (1994) 112:939–945.
   PubMed Web of Science ®Google Scholar
• PERREN MJ, FENIUK W, HUMPHREY PPA: Vascular 5-HT1-like receptors that mediate contraction of the dog Isolated saphenous vein and carotid arterial vasocon-striction in anaesthetized dogs are not of the 5-HT1A or 5-HTio subtype. Br. J. Pharmacol. (1991) 102:191–197.
   PubMed Web of Science ®Google Scholar
• DEN BOER MO, VILLALON CM, SAXENA PR: 5-HT5-likereceptors mediated changes in porcine carotid haemodynamics: are 5-HT1D-receptors involved? Naunyn-Schmiedeberg's Arch. Pharmacol. (1992) 345:509–515.
   Google Scholar
• VILLALON CM, BOM AH, HEILIGERS JPC, DEN BOER MO, SAXENA PR: Porcine arteriovenous anastomotic con-striction by indorenate is unrelated to 5-HT1A, 5-11*Tia, 5-HTic or 5-HT1D receptor subtype. Eur. j Pharmacol. (1990) 190:167–176.
   PubMed Web of Science ®Google Scholar
• VILLALON CM, RAMIREZ-SAN JUAN E, CASTILLO C, CASTILLO E, LOPEZ-MUNOZ FJ, TERRON JA: Pharma-cological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathecto-mized dogs. Br. J. Pharmacol. (1995) 116:2778–2784.
   PubMed Web of Science ®Google Scholar
• CLITHEROW JW, SCOPES DI, SKINGLE M, JORDAN CC, FENIUK W, CAMPBELL TB, CARTER MC, COLLINGTON EW, CONNOR HE, HIGGINS GA, BEATTIE D, KELLY HA, MITCHELL WL, OXFORD AW, WADSWORTH AH, TYERS MB: Evolution of a novel series of KN,N-dimethylamino) propy11- and piperazinylbenzanilides as the first selec-tive 5-HT10 antagonists. J. Med. Chem. (1994) 37:2253–2257.
   PubMed Web of Science ®Google Scholar
• DE VRIES P, HEILIGERS JPC, VILLALON CM, SAXENA PR: Blockade of porcine carotid vascular responses to su-matriptan by GR127935, a selective 5-HT1n receptor antagonist. Br. J. Pharmacol. (1996). In press.
   Google Scholar
• HAMBLIN MW, METCALF MA: Primary structure and functional characterisation of a human 5-HT1n type serotonin receptor. Mol. Pharmacol. (1991) 40:143–148.
   PubMed Web of Science ®Google Scholar
• WEINSHANK RI, ZGOMBICK JM, MACCHI MJ, BRANCHEK TA, HARTIG PR: Human serotoninin receptor is encoded by a subfamily of two distinct genes: 5-HTtua and 5-11Tinp. Proc. Natl. Acad. Sci. USA (1992) 89:3630–3634.
   PubMed Web of Science ®Google Scholar
• HAMEL E, FAN E, LINVILLE D, TING V, VILLEMURE J-G, CHIA L-S: Expression of mRNA for serotonin 5-hy-droxy1ryptaminemp receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol (1993) 44:242–246.
   PubMed Web of Science ®Google Scholar
• DEN BOER MO, HEILIGERS JPC, SAXENA PR: Carotid vascular effects of ergotamine and dihydroergotatnine In the pig: no exclusive mediation via 5-HTi-like recep-tors. Br. J. Pharmacol. (1991) 104:183–189.
   PubMed Web of Science ®Google Scholar
• DEN BOER MO, VILLALON CM, HEILIGERS JPC, HUM-PHREY PPA, SAXENA PR: Role of 5-HT1-like receptors in the reduction of porcine cranial arteriovenous anasto-motic shunting by sumatriptan. Br. J. Pharmacol. (1991) 102:323–330.
   PubMed Web of Science ®Google Scholar
• GLENNON RA, WESTICAEMPER RB: 5-HT1n receptors: aserotonin receptor for the 1990s. Drug News & Perspec-tives (1993) 6:390–405.
   Google Scholar
• GLENNON RA: Serotonin receptors and site selective agents. J. Physiol. Pharmacol. (1991) 1:49–60.
   Google Scholar
• GLEN RC, MARTIN GR, HILL AP, HYDE RM, WOOLLARD PM, SALMON JA, BUCKINGHAM J, ROBERTSON AD: Com-puter-aided design and synthesis of 5-substituted tryp-tamines and their pharmacology at the 5-htid receptor: discovery of compounds with potential anti-migraine properties. J. Med. Chem. (1995) 38:3566–3580.
   PubMed Web of Science ®Google Scholar
• STREET LJ, BAKER R, DAVEY WB, GUIBLIN AR, JELLEY RA, REEVE AJ, ROUTLEDGE H, STERNFELD F, WATT AP, BEER MS et al.: Synthesis and serotonergic activity of N,N-di- methyl-245-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yllet hylamine and analogues: potent agonists for 5-HT10 receptors. J. Med. Chem. (1995) 38:1799–1810.
   PubMed Web of Science ®Google Scholar
• CONNOR H, O'SHAUGHNESSY CT, FENIUK W, PERREN MJ, NORTH PC, OXFORD AW, BUTINA D, OWEN M, HUM-PHREY PPA: GR85548, a potent selective agonist for the intracranial vascular 5-HT1 receptor. Br. J. Pharmacol. (1993) 108:99P.
   Web of Science ®Google Scholar
• YOCCA FD, BUCHANEN I, GYLYS IA, HAMEL E, IBEN LG, IZZARELLI DG, MAHLE CD, MYERS R, NOONEN JW, PARKER EM, WILLIAMS AD, SARBIN N, SAXENA PR, SMITH DW, WIENER HL: The preclinical pharmacological pro-file of the putative antimigraine agent BMS-180048, a structurally novel 5-HTto agonist Cephalalgia (1995) 15\(Suppl. 14):174.
   Google Scholar
• VAN DE WATER A, D'AUBIOUL J, VAN GERVEN W, VAN AMMEL K, DE CLERCK F: Selective vasoconstriction by ahlitiitan in the carotid bed of anaesthetized dogs. Eur. Pharmacol. (1996) 299:127–137.
   PubMed Web of Science ®Google Scholar
• VISSER WH, KLEIN KB, COX RC, JONES D, FERRARI MD: 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology (1996) 46: 522–526.
   PubMed Web of Science ®Google Scholar
• CUTLER NR, CLAGHORN J, SRAMEK JJ, BLOCK G, PANEBI-ANCO D, CHENG H, OLAH JV, REINES SA: Pilot study of MK-462 in migraine. Cephalalgia (1996) 16:113–116.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN J, SCHELLENS R, DIENER HC, DAHLOF C, OLESEN J, SENARD JM, STEINER T, SIMARD D, VINGER-HOEDS I (ON BEHALF OF THE ALNIDITAN SC DOSE-FIND-ING STUDY GROUP): Alniditan, a novel non-indole 5-HTID-receptor agonist: a sc dose-finding trial. Poster at the 6th International Headache Research Seminar Head-ache treatment, Trial Methodology and New Drugs. Copen-hagen (November 17–19, 1995).
   Google Scholar
• BEER MS, MIDDLEMISS DN, STANTON JA, LONGMORE J,HARGREAVES RJ, NOBLE AJ, SCHOLEY KS, BEVAN Y, HILL RG, BAKER R, STREET LJ, MATASSA VG, IVERSEN LL: In vivo pharmacological profile of the novel 5-HTm recep-tor agonist M1(-462. Poster at the 7th International Congress of Headache. Toronto (1995).
   Google Scholar
• LEYSEN JE, GOMMEREN W, LUYTEN WHML, VAN-HOENACKER P, HAEGEMAN G, LESAGE AS: [311j-Alniditan, a new high affinity agonist ligand for human 5HTtoor and 5HTtop-receptors. Abstract Neuroscience Meeting (1995).
   Google Scholar
• MARTIN GR, DIXON R: Pre-c.lhilcal and clinical pharma-cology of the novel anthnigraine compound 311C90. Poster at the American Association for the Study of Headache (1995).
   Google Scholar
• ZGOMBICK JM, BORDEN LA, COCHRAN TL, KUCHAREWICZ SA, WEINSHANK RI, BRANCHEK TA: Dual coupling of cloned human 5-hydroxytryptaminetna and 5-hydroxytryptamine1np receptors stably ex-pressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concen-trations via pertussis toxin-sensitive G protein(s). Mol. Pharmacol. (1993) 44:575–582.
   PubMed Web of Science ®Google Scholar
• MACLEAN MR, CLAYTON RA, HILLIS SW, MCINTYRE PD,PEACOCK AJ, 'TEMPLETON AG: 5-HT1-receptor-mediated vasoconstriction in bovine isolated pulmonary arteries: influences of vascular endothelium and tone. Pulm. Pharmacol (1994) 7:65–72.
   PubMedGoogle Scholar
• COCKS TM, KEMP BK, PRUNEAU D, ANGUS _IA: Compari-son of contractile responses to 5-hydroxytryptamitte and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619. Br. J. Pharmacol. (1993) 110:360–368.
   PubMed Web of Science ®Google Scholar
• MASSENVANDENBRINK A, BAR WA, FERRARI MD, BOS E, SAXENA PR: Endogenously produced thromboxane in-volved in sumatriptan-induced contraction of the hu-man isolated coronary artery. Cephalalgia (1995) 15\(Suppl. 14):113.
   Google Scholar
• BOULANGER CM, LONGMORE J, DESTA B, SCHOFIELD W: Further studies on the response of human coronary arteries to the 5-HT1n receptor agonists sumatriptan and MK-462. Br. J. Pharmacol. (1995) 116:38P.
   Web of Science ®Google Scholar
• FERRO A, LONGMORE J, HILL RJ, BROWN MJ: A compari-son of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br. J. Clin. Pharmacol. (1995) 40:245–51.
   PubMed Web of Science ®Google Scholar
• SAXENA PR, VERDOUW PD: Effects of methysergide and 5-hydroxyiryptamine on carotid blood flow distribu-tion in pigs: further evidence for the presence of atypi-cal 5-HT receptors. Br. J. Phannacol. (1984) 82:817–826.
   Web of Science ®Google Scholar
• PERREN MJ, FENIUK W, HUMPHREY PPA: The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia (1989) 9\(Suppl. 9):41–46.
   Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, BAKER R, STREET LJ, MATASSA VG, BEER MS, MIDDLEMISS DN, IVERSEN LL, HILL RG, HARGREAVES RJ: In vivo pharmacology of the novel 5-HTm receptor agonist MK-462. Poster at the International Congress of Headache. Toronto (1995).
   Google Scholar
• SAXENA PR, DE VRIES P, WANG W, HEILIGERS JPC, YOCCA FD: Carotid vascular effects of BMS-180048, a new 5-HTip receptor agonist, in anaesthetized pigs. 3rd Euro-pean Headache Federation Meeting. Sardinia, Italy (1996).
   Google Scholar
• PERREN MJ, CONNOR H, FENIUK W, NORTH PC, SAYNOR DA, HUMPHREY PPA: Pharmacological activity in vivo of GR85548, a selective 5-HT: receptor agordst. Br. J. Phar-macol. (1993) 108:260P.
   Web of Science ®Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mecha-nisms of action of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. (1992) 13:307–311.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin 5-11T1n receptor agonist 311C90. Headache (1994) 34:394–399.
   Google Scholar
• GOADSBY PJ, HOSKIN KL: Trigeminal neuronal activity Is inhibited by intravenous administration of 311C90 in the cat. Poster at the American Association for the Study of Headache (1995).
   Google Scholar
• SAXENA PR: Discovering migraine mechanisms fromanimal experiments- Discussion snmmAry. In: Experi-mental Headache Models. Olesen J, Moskowitz MA (Eds.), Lippincott-Raven Publishers, New York (1995):119–122.
   Google Scholar
• EDVINSSON L, GOADSBY PJ: Neuropeptides in migraineand cluster headache. Cephalalgia (1994) 14:320–327.
   PubMed Web of Science ®Google Scholar
• BUTLER A, WORTON SP, O'SHAUGHNESSY CT, CONNORHE: Sensory nerve-mediated relaxation of guinea-pig Isolated pulmonary artery: prejunctional modulation by a2-adrenoceptor agonists but not sumatriptan. Br. J. Pharmacol. (1993) 109:126–130.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY CT, WALDRON GJ, CONNOR HE: Lack of effect of sumatriptan and UK-14,304 on capsaicin-in-duced relaxation of guinea-pig isolated basilar artery. Br. J. Pharmacol. (1993) 108:191–195.
   PubMed Web of Science ®Google Scholar
• Escarr KJ, BEATTIE DT, CONNOR HE, BRAIN SD: The modulation of the increase in rat facial skin blood flow observed after trigeminal ganglion stimulation. Eur. J. Pharmacol. (1995) 284:69–76.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY CT, CONNOR HE: Activation of sensorynerves in guinea-pig isolated basilar artery by nicotine: evidence for inhibition of trigeminal sensory neuro-transmission by sumatriptan. Eur. J. Pharmacol. (1994) 259:37–42.
   PubMed Web of Science ®Google Scholar
• KAUBE H, HOSKIN KL, GOADSBY PJ: Inhibition by suma-triptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. (1993) 109:788–792.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY CT, CONNOR HE, FENIUK W: Extracel-lular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia (1993) 13:175–179.
   PubMed Web of Science ®Google Scholar
• ZOCHODNE DW, HO LT: Sumatriptan blocks neurogenic Inflammation in the peripheral nerve trunk. Neurology (1994) 44:161–163.
   PubMed Web of Science ®Google Scholar
• HUSSEY EK, DONN KH, BUSCH MA, FOX AW, POWELL JR:Pharmacokinetics (PK) of oral sumatriptan in migraine patients during an attack and while painfree. Clin. Pharmacol. Ther. (1991) 49:134.
   Web of Science ®Google Scholar
• DIXON R, ON N, POSNER J: Oral bioavailabillty of the novel 5-HTio agonist 311C90. Poster at the 7th Interna-tional Congress of Headache. Toronto (1995).
   Google Scholar
• SEABER E, ON N, PHILLIPS S, CHURCHUS R, POSNER J, ROLAN P: The tolerability and pharmacokinetics of the novel antirnigraine compound 311C90 in healthy male volunteers. Br. J. Clin . Pharmacol. (1996) 41:141–147.
   PubMed Web of Science ®Google Scholar
• CHENG HY, POLVINO WJ, SCIBERRAS D, YOGENDRAN L, CERCHIO KA, CHRISTIE K, OLAH TV, MCLOUGHLIN D, JAMES 1, ROGERS JD: Pharmacokinetics and food inter-action of MK-462 in healthy males. Biopbarm. Drug Dispos. (1996) 17:17–24.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, GOADSBY PJ: The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14:401–410.
   PubMed Web of Science ®Google Scholar
• VAN ES NM, BRUNING TA, CAMPS J, CHANG PC, BLAUWGJ, FERRARI MD, SAXENA PR, VAN ZWIETEN PA: Assess-ment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia (1995) 15:288–291.
   PubMed Web of Science ®Google Scholar
• FRIBERG L, OLESEN J, IVERSEN HK, SPERLING B: Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. lancet (1991) 338:13–17.
   PubMed Web of Science ®Google Scholar
• CAEKEBEKE JFV, FERRARI MD, ZWETSLOOT CP, JANSEN J, SAXENA PR: Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology (1992) 42:1522–1526.
   PubMed Web of Science ®Google Scholar
• OLESEN J, IVERSEN HK, THOMSON LL: Nitric oxide su-persensitivity: a possible molecular mechanism of mi-graine pain. NeuroReport (1993) 4:1027–1030.
   PubMed Web of Science ®Google Scholar
• OLESEN J, THOMSEN, LL, IVERSEN H: Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol. Sci. (1994) 15:149–153.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, HILL RG, HARGREAVESRJ: The non-peptide neurokinina receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br. J. Pharmacol. (1993) 108: 11–12.
   PubMed Web of Science ®Google Scholar
• CUTRER FM, SCHOENFELD D, LIMMROTH V, PANAHIANN, MOSKOWITZ MA: Suppression by the sumatriptan analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudal& induced by intracisternal capsaicin. Br.J. Pharmacol. (1995) 114:987–992.
   PubMed Web of Science ®Google Scholar
• KAJEKAR R, GUPTA P, SHEPPERSON NB, BRAIN SD: Effectof a 5-HT1 receptor agonist, CP-122,288, on oedema formation induced by stimulation of the rat saphenous nerve. Br. J. Pharmacol. (1995) 115:1–2.
   PubMed Web of Science ®Google Scholar
• NOZAKI K, MOSKOWITZ MA, BOCCALINI P: CP-93,129,sumatriptan, dihydroergotamine block c-fos expres-sion within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br. J. Pharmacol. (1992) 106:409–415.
   PubMed Web of Science ®Google Scholar